ESR1 and cancer: In this regard, it should be noted that the stimulatory effects on cancer progression elicited by estrogens via both ERα and GPER and by ERα antagonists through GPER address the need to discover novel drugs targeting simultaneously both receptors, in order to obtain major therapeutic benefits in respect to the use of the current selective antagonists.